Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis

T Kalincik; D Horakova; T Spelman; V Jokubaitis; M Trojano; A Lugaresi; G Izquierdo; C Rozsa; P Grammond; R Alroughani; P Duquette; M Girard; E Pucci; J Lechner-Scott; M Slee; R Fernandez-Bolanos; F Grand'Maison; R Hupperts; F Verheul; S Hodgkinson; C Oreja-Guevara; D Spitaleri; M Barnett; M Terzi; R Bergamaschi; P McCombe; J Sanchez-Menoyo; M Simo; T Csepany; G Rum; C Boz; E Havrdova; H Butzkueven

Journal article

Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis

T Kalincik, D Horakova, T Spelman, V Jokubaitis, M Trojano, A Lugaresi, G Izquierdo, C Rozsa, P Grammond, R Alroughani, P Duquette, M Girard, E Pucci, J Lechner-Scott, M Slee, R Fernandez-Bolanos, F Grand'Maison, R Hupperts, F Verheul, S Hodgkinson Show all

Annals of Neurology | WILEY | Published : 2015

DOI: 10.1002/ana.24339

Download PDF

Abstract

Objective: In patients suffering multiple sclerosis activity despite treatment with interferon β or glatiramer acetate, clinicians often switch therapy to either natalizumab or fingolimod. However, no studies have directly compared the outcomes of switching to either of these agents. Methods: Using MSBase, a large international, observational, prospectively acquired cohort study, we identified patients with relapsing-remitting multiple sclerosis experiencing relapses or disability progression within the 6 months immediately preceding switch to either natalizumab or fingolimod. Quasi-randomization with propensity score-based matching was used to select subpopulations with comparable baseline ..

View full abstract

University of Melbourne Researchers

Tomas Kalincik Author

Timothy Spelman Author

Related Projects (5)

TREATING PROGRESSIVE MULTIPLE SCLEROSIS

While there are numerous therapies for relapsing-remitting multiple sclerosis (MS), therapy for progressive MS remains elusive. This project..

PRECISION TREATMENT FOR MULTIPLE SCLEROSIS: MAXIMISING THE EFFECT OF IMMUNOMODULATORY THERAPY

Response to therapy varies greatly among patients with multiple sclerosis (MS). The current lack of individualised MS therapy may lead to su..

PRECISION THERAPY FOR NEUROLOGICAL DISEASES

Multiple sclerosis is the most common cause of neurological disability among young adults. The patients’ individual response to therapy is h..

SELECTING OPTIMAL TREATMENT FOR PATIENTS WITH MULTIPLE SCLEROSIS

Multiple sclerosis is the most common cause of neurological disability among young people. With the increasing choice of therapies, the goal..

CENTRE FOR TRANSLATIONAL NEUROSCIENCE: A MODULAR PLATFORM FOR TRANSLATING DISCOVERY INTO HEALTH OUTCOMES

Clinical Centre of Research Excellence in Translational Neuroscience will provide people, pathways and resources to create a novel platform ..

Grants

Awarded by National Health and Medical Research Council

Funding Acknowledgements

This work was supported by the Multiple Sclerosis Research Australia Postdoctoral Fellowship (11-054, to T.K.), National Health and Medical Research Council (NHMRC) Early Career Fellowship (1071124, to T.K.), NHMRC Career Development Award (628856, to H.B.), NHMRC Project Grant (1032484, to H.B.), NHMRC Centre for Research Excellence (1001216, to H.B.), and MSBase Foundation. The MSBase Foundation is a not-for-profit organization that receives support from Merck Serono, Biogen Idec, Novartis Pharma, Bayer Schering, Sanofi-Aventis, and BioCSL. D.H. and E.H. are recipients of the Charles University in Prague Project Grant (PRVOUK-P26/LF1/4) and Czech Ministry of Health Project Grant (NT13237-4/2012).